Interferon News and Research

RSS

Long-term interferon beta benefits unclear in MS

A large “real-world” study fails to show reduced disability progression in patients with relapsing-remitting multiple sclerosis given interferon beta.

26 Jul 2012

Vitamin B12 supplements and hepatitis C treatment: an interview with Gerardo Nardone and Alba Rocco

Since its discovery in 1989, hepatitis C virus (HCV) has been recognized as a major cause of chronic liver disease worldwide. The most recent WHO estimate of the prevalence of HCV infection is 2%, representing . about 150 million people. Every year, 3–4 million new people are infected with the hepatitis C virus, of those, approximately 60–80% develop chronic hepatitis, and 30% of them progress to cirrhosis and to end-stage liver disease.

26 Jul 2012

Herbal therapy no alternative in HCV infection

The commonly used herbal remedy, silymarin, offers no benefit to patients with treatment-resistant hepatitis C virus infection, a study shows.

23 Jul 2012

Researchers uncover protein structure that regulates blood cell formation and activity

A Finnish research team together with researchers from New York, USA, has uncovered a protein structure that regulates cell signalling and the formation of blood cells. The team's results, published in Nature Structural & Molecular Biology, the most prestigious journal in the field, shed light on the mechanisms at play in haematological disorders and provide new opportunities for the design of disease-specific treatment.

23 Jul 2012

Silymarin does not offer significant improvements for patients with HCV

Silymarin, an extract of milk thistle commonly used to treat chronic liver disease by millions of people around the World, does not offer significant improvements for patients, according to a new study conducted by a nationwide group of researchers including faculty at the Perelman School of Medicine at the University of Pennsylvania.

20 Jul 2012

Interferon beta not associated with less progression of disability in patients with RRMS

Among patients with relapsing-remitting multiple sclerosis (MS), treatment with the widely-prescribed drug to treat MS, interferon beta, was not associated with less progression of disability, according to a study in the July 18 issue of JAMA.

18 Jul 2012

Silymarin does not provide greater benefit for patients with chronic HCV infection

Use of the botanical product silymarin, an extract of milk thistle that is commonly used by some patients with chronic liver disease, did not provide greater benefit than placebo for patients with treatment-resistant chronic hepatitis C virus (HCV) infection, according to a study in the July 18 issue of JAMA.

18 Jul 2012

Hepatitis C treatment may be helped by vitamin B12 supplements

Adding vitamin B12 to standard hepatitis C virus (HCV) treatment significantly boosts the body’s ability to keep the virus at bay, indicates a pilot study published online in the journal Gut.

18 Jul 2012

Altered immune function in relatives of schizophrenia patients

Schizophrenia patients and their unaffected first-degree relatives exhibit immune system alterations compared with mentally healthy individuals, researchers report.

12 Jul 2012

Altered immune function in relatives of schizophrenia patients

Schizophrenia patients and their unaffected first-degree relatives exhibit immune system alterations compared with mentally healthy individuals, researchers report.

10 Jul 2012

Neuroprotective effects underpin fingolimod benefits in MS

Fingolimod therapy reduces inflammatory activity and tissue loss in the brains of patients with multiple sclerosis, shows further analysis of the FREEDOMS trial.

10 Jul 2012

Fingolimod offers minor added benefit for patients with RRMS

The immunosuppressive drug fingolimod (trade name: Gilenya-) is approved for the treatment of highly-active relapsing-remitting multiple sclerosis (RRMS) in adults. In an early benefit assessment pursuant to "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) assessed whether fingolimod offers an added benefit compared with the present standard therapy.

6 Jul 2012

Medivir, Bristol-Myers Squibb to initiate TMC435 and daclatasvir phase II combination study in HCV

Medivir AB, the research-based pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that a phase II combination study with the investigational compound TMC435 and Bristol-Myers Squibb's investigational compound daclatasvir will start in July.

29 Jun 2012

AASLD, EASL to hold special conference on therapy of HCV

The European Association for the Study of the Liver (EASL), together with the American Association for the Study of Liver Diseases (AASLD), will be holding an exciting "Special Conference" dedicated to the timely topic of: Therapy of Hepatitis C: Clinical Application and Drug Development.

29 Jun 2012

UTMB researchers improve existing experimental vaccine for Rift Valley fever virus

University of Texas Medical Branch researchers have significantly improved an existing experimental vaccine for Rift Valley fever virus, making possible the development of a more effective defense against the dangerous mosquito-borne pathogen.

28 Jun 2012

FDA grants Orphan Drug Designation to Medgenics’ INFRADURE Biopump

Medgenics, Inc., the developer of Biopump, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that its INFRADURE Biopump has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for the treatment of hepatitis D.

21 Jun 2012

Evidence mounts for vitamin D multiple sclerosis role

Three studies published in Neurology add weight to the theory that vitamin D levels have an important effect on relapse rates and cerebral lesions in patients with multiple sclerosis.

20 Jun 2012

Researchers unlock structure of STING protein

Researchers at Weill Cornell Medical College have unlocked the structure of a key protein that, when sensing certain viruses and bacteria, triggers the body's immediate immune response.

20 Jun 2012

Commensal bacteria essential to fight off viral infections

Healthy humans harbor an enormous and diverse group of bacteria and other bugs that live within their intestines. These microbial partners provide beneficial aid in multiple ways - from helping digest food to the development of a healthy immune system.

19 Jun 2012